REFERENCES
manic, bipolar I depression, sleep disturbance symptoms, depressive, irritability
REMISSION
Associations of sleep disturbance symptoms (“bridge symptoms”) with depressive and manic symptom clusters in children and adolescents with bipolar I depression.Baseline “decreased need for sleep” (YMRS item 4) and improvement in overall depressive symptom cluster at week-6 endpoint with lurasidone (Decreased need for sleep (YMRS item 4) and “irritability” (YMRS item 5) at study baseline and improvement in overall depressive symptom cluster at week-6 endpoint with lurasidone (“Decreased need for sleep” (YMRS item 4) at extension baseline and improvement in sleep difficulty and overall depressive symptom severity in youth participants treated with lurasidone in both acute 6-week and 2-year open-label extension studies. Legend: *“Irritability” (YMRS item 5) at extension baseline and improvement in overall depressive symptom severity in youth participants treated with lurasidone in both acute 6-week and 2-year open-label extension studies. Legend: *“Decreased need for sleep” (YMRS item 4) and “irritability” (YMRS item 5) at extension baseline and improvement in overall depressive symptom severity in youth participants treated with lurasidone in both acute 6-week and 2-year open-label extension studies. Legend: *“Decreased need for sleep” (YMRS item 4) and “irritability” (YMRS item 5) at extension baseline and improvement in global functioning in youth participants treated with lurasidone in both acute 6-week and 2-year open-label extension studies. Legend: *“Decreased need for sleep” (YMRS item 4) and “irritability” (YMRS item 5) at the extension baseline and the rate of sustained recovery in youth participants treated with lurasidone in both acute 6-week and 2-year open-label extension studies. Legend: Sustained recovery was defined as achieving both symptomatic remission (CDRS-R score ≤ 28) and functional remission (CGAS score ≥ 71) criteria for 6 months or longer (2 consecutive visits).The demographic and clinical characteristics of the intent-to-treat study sample at baseline.